Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Utidelone Capsule in Advanced Solid Tumors
NCT05681000Phase 1Unknown
- Sponsor
- Beijing Biostar Pharmaceuticals Co., Ltd.
- Start
- Jun 2023
- Primary completion
- Apr 2024
- Modality
- Allosteric Modulators
- Countries
- 1
01
Overview
Phase 1, open-label trial of utidelone in solid tumor (advanced stage) (6 arms), sponsored by Beijing Biostar Pharmaceuticals Co., Ltd. Primary endpoints: Maximum Tolerated Dose at 12 months and Dose-Limiting Toxicity at 12 months. Status: unknown.
02
Drugs
utidelone
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT05681000.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05681000.